Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

NCT03552276 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

281

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: SUNPG18_07 I (Tildrakizumab 200 mg)
DRUG: SUNPG18_07 II (Tildrakizumab 100 mg)

Sponsor

Sun Pharmaceutical Industries Limited